Volume 153, Issue 3, Pages e2 (September 2017)

Slides:



Advertisements
Similar presentations
Volume 145, Issue 1, Pages (July 2013)
Advertisements

Risk of recurrence of Barrett’s esophagus after successful endoscopic therapy  Rajesh Krishnamoorthi, MD, Siddharth Singh, MD, Karthik Ragunathan, MD,
Volume 153, Issue 3, Pages e2 (September 2017)
The Seattle Protocol Does Not More Reliably Predict the Detection of Cancer at the Time of Esophagectomy Than a Less Intensive Surveillance Protocol 
Covering the Cover Gastroenterology
How to Manage a Barrett's Esophagus Patient With Low-Grade Dysplasia
Stuart Jon Spechler, Rhonda F. Souza  Gastroenterology 
Volume 125, Issue 3, Pages (September 2003)
Volume 135, Issue 5, Pages e2 (November 2008)
Herbert C. Wolfsen, Michael B. Wallace  Gastroenterology 
Safety and Efficacy of Endoscopic Mucosal Therapy With Radiofrequency Ablation for Patients With Neoplastic Barrett's Esophagus  William J. Bulsiewicz,
Barrett's esophagus: diagnosis and management
Covering the Cover Gastroenterology
Volume 137, Issue 5, Pages e2 (November 2009)
Survival of Patients With Superficial Esophageal Adenocarcinoma After Endoscopic Treatment vs Surgery  Saowanee Ngamruengphong, Herbert C. Wolfsen, Michael.
Effectiveness of Hepatitis B Treatment in Clinical Practice
Volume 131, Issue 5, Pages (November 2006)
Volume 152, Issue 5, Pages (April 2017)
Volume 149, Issue 3, Pages e3 (September 2015)
Metformin Does Not Reduce Markers of Cell Proliferation in Esophageal Tissues of Patients With Barrett’s Esophagus  Amitabh Chak, Navtej S. Buttar, Nathan.
Cause-Specific Mortality of People With Barrett's Esophagus Compared With the General Population: A Population-Based Cohort Study  Masoud Solaymani–Dodaran,
Volume 148, Issue 7, Pages (June 2015)
Rana Sabbagh, Edi Levi, Fadi Antaki  Gastroenterology 
Volume 154, Issue 8, Pages e5 (June 2018)
Amnon Sonnenberg, Richard H. Lash, Robert M. Genta  Gastroenterology 
American Gastroenterological Association Institute Technical Review on the Management of Gastroesophageal Reflux Disease  Peter J. Kahrilas, Nicholas.
Stuart Jon Spechler, Rhonda F. Souza  Gastroenterology 
Tissue-Engineered Cell Sheets for Stricture Prevention: A New Connection Between Endoscopy and Regenerative Medicine  Joshua D. Penfield, Emmanuel C.
Volume 142, Issue 2, Pages (February 2012)
Volume 153, Issue 3, Pages e16-e17 (September 2017)
Radiofrequency Ablation of Barrett's Esophagus Reduces Esophageal Adenocarcinoma Incidence and Mortality in a Comparative Modeling Analysis  Sonja Kroep,
Volume 154, Issue 4, Pages (March 2018)
A Rare Cause of Postprandial Abdominal Pain and Nausea
Volume 143, Issue 2, Pages (August 2012)
A Cost-Utility Analysis of Ablative Therapy for Barrett's Esophagus
Association Between Length of Barrett's Esophagus and Risk of High-grade Dysplasia or Adenocarcinoma in Patients Without Dysplasia  Rajeswari Anaparthy,
Sibu Varghese, Pierre Lao–Sirieix, Rebecca C. Fitzgerald 
Barrett's esophagus: diagnosis and management
Prateek Sharma, MD, Sachin Wani, MD, Amit Rastogi, MD 
Volume 141, Issue 4, Pages e1 (October 2011)
Volume 143, Issue 3, Pages e1 (September 2012)
Optimal Histologic Cutpoints for Treatment Response in Patients With Eosinophilic Esophagitis: Analysis of Data From a Prospective Cohort Study  Craig.
Volume 136, Issue 1, Pages (January 2009)
Endoscopic Therapy for Barrett's Esophagus
Efficacy and Durability of Radiofrequency Ablation for Barrett's Esophagus: Systematic Review and Meta-analysis  Eric S. Orman, Nan Li, Nicholas J. Shaheen 
Covering the Cover Gastroenterology
Volume 141, Issue 2, Pages (August 2011)
Volume 143, Issue 4, Pages e1 (October 2012)
Patients With Nondysplastic Barrett's Esophagus Have Low Risks for Developing Dysplasia or Esophageal Adenocarcinoma  Sachin Wani, Gary Falk, Matthew.
White Paper AGA: Advanced Imaging in Barrett’s Esophagus
Volume 134, Issue 1, Pages (January 2008)
Ashwin N. Ananthakrishnan, David Lieberman  Gastroenterology 
Jeremy P. Dwyer, Patrick Hosking, John Lubel  Gastroenterology 
Volume 145, Issue 1, Pages (July 2013)
The Rise and Fall (and Rise?) of Endoscopic Anti-Reflux Procedures
Secondary Prophylaxis of Hepatic Encephalopathy: An Open-Label Randomized Controlled Trial of Lactulose Versus Placebo  Barjesh Chander Sharma, Praveen.
Association of Barrett's Esophagus With Type II Diabetes Mellitus: Results From a Large Population-based Case-Control Study  Prasad G. Iyer, Bijan J.
Volume 135, Issue 5, Pages e2 (November 2008)
Volume 145, Issue 5, Pages e3 (November 2013)
A Necrotic Liver Mass Gastroenterology
Volume 152, Issue 3, Pages e4 (February 2017)
Volume 145, Issue 3, Pages e1 (September 2013)
Electronic Clinical Challenges and Images in GI
Prateek Sharma, Gary W. Falk, Allan P
Su1127 POST-PROCEDURAL PAIN PROFILE ASSOCIATED WITH THE USE OF A NOVEL CONTACT CRYOBALLOON FOCAL ABLATION SYSTEM FOR NEOPLASTIC BARRETT'S ESOPHAGUS 
Statin Use Is Associated With a Decreased Risk of Barrett’s Esophagus
Low-grade dysplasia in Barrett’s esophagus
Neil Gupta, Joel V. Brill, Marcia Canto, Daniel DeMarco, Brian M
Metformin Does Not Reduce Markers of Cell Proliferation in Esophageal Tissues of Patients With Barrett’s Esophagus  Amitabh Chak, Navtej S. Buttar, Nathan.
A Rare Tumor of the Liver With a Sudden Presentation
Presentation transcript:

Volume 153, Issue 3, Pages 681-688.e2 (September 2017) Late Recurrence of Barrett’s Esophagus After Complete Eradication of Intestinal Metaplasia is Rare: Final Report From Ablation in Intestinal Metaplasia Containing Dysplasia Trial  Cary C. Cotton, W. Asher Wolf, Bergein F. Overholt, Nan Li, Charles J. Lightdale, Herbert C. Wolfsen, Sarina Pasricha, Kenneth K. Wang, Nicholas J. Shaheen Richard E. Sampliner, David E. Fleischer, Virender K. Sharma, Glenn M. Eisen, M. Brian Fennerty, John G. Hunter, Mary P. Bronner, John R. Goldblum, Ana E. Bennett, Hiroshi Mashimo, Richard I. Rothstein, Stuart R. Gordon, Steven A. Edmundowicz, V. Raman Muthusamy, Kenneth J. Chang, Michael B. Kimmey, Stuart J. Spechler, Ali A. Siddiqui, Rhonda F. Souza, Anthony Infantolino, John A. Dumot, Gary W. Falk, Blair A. Jobe, Robert H. Hawes, Brenda J. Hoffman, Prateek Sharma, Amitabh Chak Cary C. Cotton, W. Asher Wolf, Bergein F. Overholt, Nan Li, Charles J. Lightdale, Herbert C. Wolfsen, Sarina Pasricha, Kenneth K. Wang, Nicholas J. Shaheen Richard E. Sampliner, David E. Fleischer, Virender K. Sharma, Glenn M. Eisen, M. Brian Fennerty, John G. Hunter, Mary P. Bronner, John R. Goldblum, Ana E. Bennett, Hiroshi Mashimo, Richard I. Rothstein, Stuart R. Gordon, Steven A. Edmundowicz, V. Raman Muthusamy, Kenneth J. Chang, Michael B. Kimmey, Stuart J. Spechler, Ali A. Siddiqui, Rhonda F. Souza, Anthony Infantolino, John A. Dumot, Gary W. Falk, Blair A. Jobe, Robert H. Hawes, Brenda J. Hoffman, Prateek Sharma, Amitabh Chak  Gastroenterology  Volume 153, Issue 3, Pages 681-688.e2 (September 2017) DOI: 10.1053/j.gastro.2017.05.044 Copyright © 2017 AGA Institute Terms and Conditions

Figure 1 Inclusion of 119 patients in the durability cohort allowing interim “touch-up” treatments and 110 patients in the analysis of recurrence not allowing “touch-up” treatments. Gastroenterology 2017 153, 681-688.e2DOI: (10.1053/j.gastro.2017.05.044) Copyright © 2017 AGA Institute Terms and Conditions

Figure 2 Estimated proportion of subjects with any recurrence stratified by baseline histologic grade after CEIM not allowing interim “touch-up” treatments. Gastroenterology 2017 153, 681-688.e2DOI: (10.1053/j.gastro.2017.05.044) Copyright © 2017 AGA Institute Terms and Conditions

Figure 3 Estimated proportion of subjects with any recurrence after CEIM not allowing interim “touch-up” treatments. Gastroenterology 2017 153, 681-688.e2DOI: (10.1053/j.gastro.2017.05.044) Copyright © 2017 AGA Institute Terms and Conditions

Figure 4 Estimated hazard function, or instantaneous rate, for recurrence of intestinal metaplasia following CEIM not allowing interim “touch-up” treatments. Gastroenterology 2017 153, 681-688.e2DOI: (10.1053/j.gastro.2017.05.044) Copyright © 2017 AGA Institute Terms and Conditions

Supplementary Figure 1 Estimated proportion of subjects with incidence of any recurrence stratified by baseline histologic grade after CEIM defined as 2 clean endoscopies not allowing interim “touch-up” treatments. Gastroenterology 2017 153, 681-688.e2DOI: (10.1053/j.gastro.2017.05.044) Copyright © 2017 AGA Institute Terms and Conditions

Supplementary Figure 2 Estimated proportion of subjects with incidence of any recurrence after CEIM not allowing interim “touch-up” treatments. Gastroenterology 2017 153, 681-688.e2DOI: (10.1053/j.gastro.2017.05.044) Copyright © 2017 AGA Institute Terms and Conditions

Supplementary Figure 3 Estimated hazard function, or instantaneous rate, for recurrence of intestinal metaplasia following CEIM not allowing interim “touch-up” treatments. Gastroenterology 2017 153, 681-688.e2DOI: (10.1053/j.gastro.2017.05.044) Copyright © 2017 AGA Institute Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.